<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713736</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0539</org_study_id>
    <nct_id>NCT03713736</nct_id>
  </id_info>
  <brief_title>Papillomavirus Load in Rheumatic Inflammatory Diseases</brief_title>
  <acronym>PAPLOR</acronym>
  <official_title>Papillomavirus Load in Rheumatic Inflammatory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are the two most common chronic
      inflammatory rheumatism, with a prevalence in the French population of 0.3% and 0.4%,
      according to the criteria European League Against Rheumatism / American College of
      Rheumatology (EULAR / ACR) 2010 and Assessemnt of SpondyloArthritis International Society
      (ASAS) 2009 respectively. In patients whose pathology is resistant to first-line treatment,
      such as methotrexate for rheumatoid arthritis and peripheral spondyloarthritis, or
      non-steroidal anti-inflammatory drugs for axial spondyloarthritis, the treatment is based on
      biotherapies, such as anti-inflammatory drugs. -TNF, to obtain effective control of the
      disease and prevent joint damage.

      Human papillomavirus (HPV) infection, the leading risk factor for cervical carcinoma, is the
      most common sexually transmitted infection (STI) with a particularly high prevalence among
      young women.

      In addition, anti-TNF, used in the treatment of RA and SpA, and anti-IL6 receptor, used in
      that of RA, could have opposite effects on HPV-dependent oncogenesis.

      Thus, patients with RA or SpA may have a higher risk than the general population of
      progression to cervical cytological abnormalities. Evaluation of the chronic carriage of HPV
      would then be a useful tool in the management of these patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of papillomavirus chronic load in women with rheumatic inflammatory diseases (rheumatoid arthritis and spondyloarthritis), compared to the prevalence in general population</measure>
    <time_frame>At the end of the 24 months follow-up.</time_frame>
    <description>Papillomavirus chronic load is defined as a positive HPV test at the end of the study combined with at least 3 positive HPV tests during the 24 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the prevalence of HPV infections, whatever the type of HPV</measure>
    <time_frame>At enrollment</time_frame>
    <description>Number of patients with a positive HPV test at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of HPV infection in women with a negative HPV test at enrollment.</measure>
    <time_frame>At 24 months.</time_frame>
    <description>Number of patients with a negative HPV test at enrollment and having at least one positive HPV test during the 24 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the clearance of HPV with women with appositive HPV test at enrollment</measure>
    <time_frame>At 24 months</time_frame>
    <description>Number of patients with a positive HPV test at enrollment and having a negative HPV test at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of cytological abnormalities in women with normal cytology at enrollment according to HPV chronic load and type.</measure>
    <time_frame>At 24 months.</time_frame>
    <description>Number of patients with low-grade and high-grade cytological abnormalities during follow-up among those who had normal cytology at enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the evolution (regression, persistence or invasion) of cytological abnormalities in women with abnormal cytology at enrollment and according to HPV chronic load and type.</measure>
    <time_frame>At 24 months.</time_frame>
    <description>Number of patients ,with normal cytology at enrollment, whose cervical smear indicates a regression in cytological abnormalities or a persistence of cytological abnormalities or a development of abnormalities into cervical cancer or dysplasia, during the 24 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the number of conization according to HPV chronic load and type.</measure>
    <time_frame>At 24 months.</time_frame>
    <description>Number of conization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Spondyloarthritis</condition>
  <condition>Rhumatoid Arthisis</condition>
  <arm_group>
    <arm_group_label>Female patients with spondyloarthritis or rheumatoid arthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cervical smear</intervention_name>
    <description>Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.</description>
    <arm_group_label>Female patients with spondyloarthritis or rheumatoid arthritis</arm_group_label>
    <other_name>HPV test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pregnancy test</intervention_name>
    <description>Urinary pregnancy test</description>
    <arm_group_label>Female patients with spondyloarthritis or rheumatoid arthritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sexual activity questionnary</intervention_name>
    <description>Sexual activity questionnary</description>
    <arm_group_label>Female patients with spondyloarthritis or rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman between 18 and 65 years old

          -  Patient with rheumatoid arthritis as defined in 2010 ACR/EULAR criteria or with
             spondyloarthritis as defined in 2009 ASAS criteria

          -  Patient able to understand the objectives of the study and give documented informed
             consent

          -  Patient affiliated to a social security scheme

        Exclusion Criteria:

          -  Pregnant or breastfeeding patient

          -  Patient with a history of cervical cancer

          -  Patient under juridical protection

          -  Patient unable to provide informed consent due to linguistic or psychic impairment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne COURY-LUCAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabienne COURY-LUCAS, MD</last_name>
    <phone>04 78 86 12 31</phone>
    <phone_ext>+33</phone_ext>
    <email>fabienne.coury-lucas@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of obstetrics, Femme Mère Enfant Hospital, Lyon, France</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gery Lamblin, MD</last_name>
      <phone>04.27.85.53.53</phone>
      <phone_ext>+33</phone_ext>
      <email>gery.lamblin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gery Lamblin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - service de rhumatologie</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuelle VIGNOT, MD</last_name>
      <phone>04.72.11.74.79</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuelle.vignot@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle Vignot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69 495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabienne Coury-lucas, MD</last_name>
      <phone>478861231</phone>
      <phone_ext>+33</phone_ext>
      <email>fabienne.coury-lucas@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Muriel PIPERNO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne COURY-LUCAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Paul LARBRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie HOEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV infection</keyword>
  <keyword>Spondyloarthritis</keyword>
  <keyword>Rhumatoid Arthritis</keyword>
  <keyword>Cervical smear</keyword>
  <keyword>cervical cancer screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

